ID: ALA5220894

Max Phase: Preclinical

Molecular Formula: C8H10Cl2N2O4S

Molecular Weight: 284.12

Representations

Canonical SMILES:  N.O=C(CS(=O)(=O)O)Nc1cc(Cl)cc(Cl)c1

Standard InChI:  InChI=1S/C8H7Cl2NO4S.H3N/c9-5-1-6(10)3-7(2-5)11-8(12)4-16(13,14)15;/h1-3H,4H2,(H,11,12)(H,13,14,15);1H3

Standard InChI Key:  UFSMYVGIZRSJFH-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 284.12

Molecular Weight (Monoisotopic): 282.9473

AlogP: 1.82

#Rotatable Bonds: 3

Polar Surface Area: 83.47

Molecular Species: ACID

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: -2.08

CX Basic pKa:

CX LogP: 1.62

CX LogD: -0.76

Aromatic Rings: 1

Heavy Atoms: 16

QED Weighted: 0.83

Np Likeness Score: -1.50

References

1. He R, Wang J, Yu ZH, Moyers JS, Michael MD, Durham TB, Cramer JW, Qian Y, Lin A, Wu L, Noinaj N, Barrett DG, Zhang ZY..  (2022)  Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.,  65  (20.0): [PMID:36197449] [10.1021/acs.jmedchem.2c01143]

Source

Source(1):

• Scientific Literature